1071018-55-7

Upstream product

• 884514-26-5 5-methoxy-1-(2-phenoxyphenyl)-1-((R)-piperidin-3-yl)pentan-1-ol 
• 161660-94-2 (1R,3S)-3-((tert-butoxycarbonyl)amino)cyclopentane-1-carboxylic acid 
• 163438-09-3 (R)-1-Boc-nipecotic acid 
• 634590-61-7 (4-methoxybutyl)magnesium chloride 
• 13107-20-5 (2-phenoxyphenyl)lithium 
• 1071018-45-5 (3R)-tert-butyl 3-(1-hydroxy-5-methoxy-1-(2-phenoxyphenyl)pentyl)piperidine-1-carboxylate 
• 884512-19-0 (3R)-1-(tert-butoxycarbonyl)-3-(2-phenoxybenzoyl)piperidine 
• 884510-86-5 (R)-tert-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate 
• 101-84-8 diphenylether 

Downstream Products

• 1071017-32-7 1-((3R)-1-{[(1R,3S)-3-aminocyclopentyl]carbonyl}-3-piperidinyl)-5-(methyloxy)-1[2-(phenyloxy)phenyl]-1-pentanol 

Relevant academic research and scientific papers

RENIN INHIBITORS

Disclosed are compounds of Formula I, wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration

RENIN INHIBITORS

Described are compounds which bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.